New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
It lost $9.9M on $1.6M of revenue: $602.87 for every $100. What is an income statement?
| Revenue | 1.6 | 100.0% |
|---|---|---|
| Cost of revenue | 0.0 | 0.0% |
| Gross profit | 1.6 | 100.0% |
| Research & development | −8.3 | −504.8% |
| Selling, general & admin | −4.2 | −259.1% |
| Operating income | −10.9 | −663.9% |
| Other income, net | +1.2 | 75.2% |
| Income tax | −0.2 | −14.1% |
| Net income | −9.9 | −602.9% |
| Sep '26 | Jun '26 | Mar '26 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
1.64 | 1.92 | 2.23 | 20.11 |
+1 more quarter Free account |
Gross Profit |
1.64 | 1.92 | 2.23 | 20.11 | |
R&D Expenses |
8.26 | 8.82 | — | 14.42 | |
SG&A Expenses |
4.24 | 2.49 | — | 3.53 | |
Operating Income |
(10.86) | (9.39) | 2.23 | 2.16 | |
Non-operating Interest Expenses |
— | 0.28 | — | 0.60 | |
Non-operating Income/Expense |
1.23 | 3.13 | — | (0.36) | |
| (9.63) | (6.26) | 2.23 | 1.80 | ||
Income Tax Provision |
0.23 | 0.21 | — | 0.32 | |
Income after Tax |
(9.86) | (6.48) | 2.23 | 1.47 | |
Dividends (Preferred) |
— | 0.00 | — | — | |
Net Income Common |
(9.86) | (6.48) | (17.35) | 1.47 | |
EPS (Basic) |
(0.68) | (2.62) | (7.05) | 0.61 | |
EPS (Diluted) |
(0.68) | (2.62) | (7.05) | 0.61 | |
Shares (Basic, Weighted) |
14.50 | 2.48 | 2.46 | 2.43 | |
Shares (Diluted, Weighted) |
14.50 | 2.48 | 2.46 | 2.43 | |
Gross Margin |
100.00% | 100.00% | 100.00% | 100.00% | |
EBIT Margin |
(663.94%) | (489.83%) | 100.00% | 10.74% | |
EBT margin |
(588.75%) | (326.64%) | 100.00% | 8.93% | |
Net Profit Margin |
(602.87%) | (337.70%) | (776.85%) | 7.32% | |
EBITDA |
(10.09) | (9.39) | 2.23 | 2.99 | |
EBIT |
(10.86) | (9.39) | 2.23 | 2.16 | |
Income from Continuous Operations |
(9.86) | (6.48) | (17.35) | 1.47 | |
Income from Discontinued Operations |
— | — | 0.00 | — | |
Consolidated Net Income/Loss |
(9.86) | (6.48) | (17.35) | 1.47 | |
EPS (Basic, from Continuous Ops) |
(0.68) | (2.62) | (7.05) | 0.61 | |
EPS (Diluted, from Cont. Ops) |
(0.68) | (2.62) | (7.05) | 0.61 | |
EPS (Basic, Consolidated) |
(0.68) | (2.62) | (7.05) | 0.61 | |
EPS (Diluted, Consolidated) |
(0.68) | (2.62) | (7.05) | 0.61 | |
Shares (Diluted, Average) |
— | 2.48 | 2.46 | — | |
EBITDA Margin |
(616.87%) | (489.83%) | 100.00% | 14.85% | |
Operating Cash Flow Margin |
(687.71%) | — | — | (56.15%) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026